TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8498876

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Behavior therapy (BT)
Number of subjects: 75
Study: 2888017

Group type: EXPERIMENTAL
Intervention: Glucocorticoid (30 mg/kg bolus followed by 5 mg/kg/hour infusion for 9 hours)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Glucocorticoid
Number of subjects: 223
Study: 2196240

Group type: EXPERIMENTAL
Intervention: TBF + R administered in 3 office visits over 8 weeks
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: TBF + R plus instruction in cognitive stress coping techniques administered in 5 office visits over 8 weeks
Number of subjects: 76

Group type: COMPARATOR
Intervention: HA monitoring (control group)
Number of subjects: 76
Study: 5324976

Group type: EXPERIMENTAL
Intervention: Ethanol plus amphetamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ethanol plus placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ethanol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amphetamine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ethanol-amphetamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ethanol-lactose
Number of subjects: 0
Study: 31487195

Group type: EXPERIMENTAL
Intervention: Plasma sRAGE
Number of subjects: 393
Study: 27524498

Group type: EXPERIMENTAL
Intervention: Exogenous Testosterone
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study: 26206666

Group type: EXPERIMENTAL
Intervention: Nebulized racemic salbutamol solution
Number of subjects: 112

Group type: COMPARATOR
Intervention: 3% sodium chloride (NaCl) solution
Number of subjects: 112
Study: 23612695

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: Sweeping of the membranes
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: Acupuncture and Sweeping
Number of subjects: 407

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 407
Study: 21788033

Group type: EXPERIMENTAL
Intervention: Degarelix 240/80 mg
Number of subjects: 125

Group type: COMPARATOR
Intervention: Leuprolide to Degarelix (240/80 mg or 240/160 mg)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Degarelix (continuation)
Number of subjects: 125
Study: 19364237

Group type: EXPERIMENTAL
Intervention: Evaluative conditioning (EC) with attentional resources available
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Evaluative conditioning (EC) with depleted attentional resources
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Identification task for CSs linked to US
Number of subjects: 0
Study: 17319942

Group type: COMPARATOR
Intervention: Control group selected from Health Unit attenders
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group selected from neighbourhood of cases
Number of subjects: 0
Study: 15452182

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (doxorubicin-based)
Number of subjects: 5758
Study: 12410926

Group type: EXPERIMENTAL
Intervention: Lidocaine (local anesthesia to the trigger point)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Butylscopolamine (intravenous injection)
Number of subjects: 60
Study: 9661636

Group type: EXPERIMENTAL
Intervention: Oral glucose load before surgery
Number of subjects: 18

Group type: COMPARATOR
Intervention: No oral glucose load before surgery
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Insulin infusion during post-op clamp
Number of subjects: 18

Group type: COMPARATOR
Intervention: Pre-op clamp
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both groups post-surgery
Number of subjects: 18

Group type: COMPARATOR
Intervention: Group not receiving glucose
Number of subjects: 18
Study: 9098477

Group type: EXPERIMENTAL
Intervention: Cryopreservation procedure
Number of subjects: 45
Study: 2651174

Group type: EXPERIMENTAL
Intervention: Tenoxicam 20 mg/day
Number of subjects: 144

Group type: COMPARATOR
Intervention: Sustained release indomethacin 75 mg/day
Number of subjects: 144
Study: 333568

Group type: EXPERIMENTAL
Intervention: Sydnocarb (5-15 mg)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Mephexamid
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Maprotiline
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 143

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143
Study: 31436551

Group type: EXPERIMENTAL
Intervention: Urgent-start peritoneal dialysis (USPD)
Number of subjects: 0
Study: 28128973

Group type: EXPERIMENTAL
Intervention: High-load (HL) resistance training: 3 sets of 4-6 repetitions to momentary concentric failure
Number of subjects: 33

Group type: COMPARATOR
Intervention: Low-load (LL) resistance training: 2 sets of 12-15 repetitions to momentary concentric failure
Number of subjects: 33
Study: 26297572

Group type: EXPERIMENTAL
Intervention: Emoticon placement (Green Smiley Face) next to healthful foods
Number of subjects: 297
Study: 23357210

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 2872

Group type: EXPERIMENTAL
Intervention: Combination therapy (Doxazosin + Finasteride)
Number of subjects: 2872

Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 2872

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2872
Study: 22289552

Group type: COMPARATOR
Intervention: Continuous low-dose antibiotic (n = 37)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Single-dose antibiotic (n = 31)
Number of subjects: 68
Study: 19382094

Group type: EXPERIMENTAL
Intervention: Preventive measures and interventions for CMV and BKV infections
Number of subjects: 0
Study: 17385106

Group type: EXPERIMENTAL
Intervention: Narrow-band imaging (NBI)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Conventional colonoscopy
Number of subjects: 42
Study: 15492046

Group type: EXPERIMENTAL
Intervention: Preventive case management
Number of subjects: 3079

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3079
Study: 11700857

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 9673754

Group type: EXPERIMENTAL
Intervention: BIP chemotherapy followed by radiotherapy (RT) in CT-RT Group
Number of subjects: 184

Group type: COMPARATOR
Intervention: RT alone in RT Group
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: BIP chemotherapy followed by RT in CT-RT Group (study 2)
Number of subjects: 184

Group type: COMPARATOR
Intervention: RT alone in RT Group (study 2)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Overall survival at 48 months in CT-RT Group
Number of subjects: 184

Group type: COMPARATOR
Intervention: Overall survival at 48 months in RT Group
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Estimated survival in CT-RT Group (study 2)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Estimated survival in RT Group (study 2)
Number of subjects: 184
Study: 8082875

Group type: EXPERIMENTAL
Intervention: Alprazolam (0.5 mg orally)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 2567266

Group type: EXPERIMENTAL
Intervention: Olsalazine (2 g/day)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Sulphasalazine (3 g/day)
Number of subjects: 37
Study: 31023432

Group type: EXPERIMENTAL
Intervention: Dietary fish-oil supplementation of 2.5 g/day
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 30021463

Group type: EXPERIMENTAL
Intervention: Cristália enoxaparin (Ce)
Number of subjects: 243

Group type: COMPARATOR
Intervention: Sanofi enoxaparin (Se)
Number of subjects: 243
Study: 27658691

Group type: EXPERIMENTAL
Intervention: Sabin-IPV
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Salk-IPV
Number of subjects: 1200
Study: 25175097

Group type: EXPERIMENTAL
Intervention: Depression care for people with lung cancer
Number of subjects: 142

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 142
Study: 21902859

Group type: EXPERIMENTAL
Intervention: 5-(Z) lycopene-rich meal
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Meals rich in 9-(Z) and 13-(Z) lycopene isomers
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Meals rich in (all-E) lycopene
Number of subjects: 6
Study: 19281006

Group type: EXPERIMENTAL
Intervention: Early reconstruction of complex acetabular fractures (operated on the 7th or 10th day after injury)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Early reconstruction of complex acetabular fractures
Number of subjects: 191

Group type: COMPARATOR
Intervention: Control group (operated on the 10th day after injury)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 191
Study: 17785037

Group type: EXPERIMENTAL
Intervention: E2V (1 mg) + MPA (2.5 mg)
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: E2V (2 mg) + MPA (5 mg)
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: All treatment groups (E2V and MPA combinations)
Number of subjects: 459
Study: 15097809

Group type: EXPERIMENTAL
Intervention: Iodinated oral contrast (IOC)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Water
Number of subjects: 30

Group type: COMPARATOR
Intervention: No intervention (controls)
Number of subjects: 30
Study: 11593367

Group type: EXPERIMENTAL
Intervention: Cupfeeding
Number of subjects: 56

Group type: COMPARATOR
Intervention: Bottlefeeding
Number of subjects: 56
Study: 9870472

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 15

Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 15
Study: 7988628

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (500 mg twice daily for 3 days)
Number of subjects: 12
Study: 2686417

Group type: EXPERIMENTAL
Intervention: Intravenous ciprofloxacin (200 mg every 12 hours)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Intravenous ceftazidime
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Intravenous ciprofloxacin
Number of subjects: 32
Study: 5134561

Group type: EXPERIMENTAL
Intervention: Thermography
Number of subjects: 100

Group type: COMPARATOR
Intervention: Fluorescein test
Number of subjects: 100
Study: 31930518

Group type: EXPERIMENTAL
Intervention: Cognitive Stimulation Therapy (CST) based on Roy's adaptation model
Number of subjects: 0
Study: 30707125

Group type: COMPARATOR
Intervention: Bag-valve-mask
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Non-rebreathing mask
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen
Number of subjects: 319
Study: 28566193

Group type: EXPERIMENTAL
Intervention: Active tDCS over M1‐SO
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 40
Study: 25629544

Group type: EXPERIMENTAL
Intervention: Targeted temperature management at 33°C (TTM33)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Targeted temperature management at 36°C (TTM36)
Number of subjects: 178
Study: 23991658

Group type: EXPERIMENTAL
Intervention: Edoxaban (60 mg once daily or 30 mg once daily for specific patients)
Number of subjects: 4921

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 4921

Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 4921

Group type: EXPERIMENTAL
Intervention: Edoxaban (in patients with pulmonary embolism and right ventricular dysfunction)
Number of subjects: 4921

Group type: COMPARATOR
Intervention: Warfarin (in patients with pulmonary embolism and right ventricular dysfunction)
Number of subjects: 4921
Study: 21911723

Group type: COMPARATOR
Intervention: Tamoxifen (TAM) 20 mg daily
Number of subjects: 667

Group type: EXPERIMENTAL
Intervention: Tamoxifen plus octreotide (TAM-OCT) 90 mg depot monthly for 2 years
Number of subjects: 667
Study: 17900778

Group type: EXPERIMENTAL
Intervention: Treatment-resistant schizophrenia patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment-responsive chronic schizophrenia patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study: 17214057

Group type: EXPERIMENTAL
Intervention: Radiotherapy plus Amifostine
Number of subjects: 67

Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 67
Study: 14569242

Group type: EXPERIMENTAL
Intervention: Myocardial perfusion imaging (MPI)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Esophageal scintigraphy (ES)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Cardiac events
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Esophageal dysfunction (ED)
Number of subjects: 105
Study: 10791645

Group type: EXPERIMENTAL
Intervention: Bioabsorbable poly‐L‐lactide lag screws (3 screws of 6.3 mm diameter)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Metallic screws (3 screws of 7 mm diameter)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Bioabsorbable poly‐L‐lactide lag screws
Number of subjects: 40

Group type: COMPARATOR
Intervention: Metallic screws
Number of subjects: 40
Study: 8783312

Group type: EXPERIMENTAL
Intervention: Naloxone (6 mg i.v.)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 8123107

Group type: EXPERIMENTAL
Intervention: National mammographic screening
Number of subjects: 0

Group type: COMPARATOR
Intervention: Information circulated to general practitioners
Number of subjects: 0
Study: 3730021

Group type: EXPERIMENTAL
Intervention: Flupenthixol (Fluanxol) 0.5 mg, 1 mg, and 2 mg/day
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study: 28970207

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine 400 mg/day and sulfasalazine 2000 mg/day (arm 1)
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Methotrexate plus adalimumab 40 mg/2 weeks (arm 2)
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Early remission group (387 patients)
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Overall population (610 patients)
Number of subjects: 610
Study: 24767603

Group type: EXPERIMENTAL
Intervention: Low-intensity online CBT-based treatment consisting of six weekly modules; participants receive weekly post-session feedback.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting-list control group; participants do not receive the intervention during the waiting period.
Number of subjects: 0
Study: 22864500

Group type: EXPERIMENTAL
Intervention: Diabetes care quality improvement initiative adapted for FQHCs
Number of subjects: 0
Study: 20339354

Group type: EXPERIMENTAL
Intervention: Hourly mean method
Number of subjects: 422
Study: 18823460

Group type: EXPERIMENTAL
Intervention: Pre-operative i.v. fluid loading with a balanced crystalloid solution (1 ml/kg/h over 48 h)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (no pre-operative fluid loading)
Number of subjects: 44
Study: 15912340

Group type: EXPERIMENTAL
Intervention: Hearing aids
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (no hearing aids)
Number of subjects: 15
Study: 12043481

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluoxetine (SSRI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Preventive intervention programmes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clinic-based interventions for suicidal adolescents
Number of subjects: 0
Study: 10614059

Group type: EXPERIMENTAL
Intervention: Diet high in saturated fat
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diet high in polyunsaturated fat
Number of subjects: 0
Study: 7595953

Group type: EXPERIMENTAL
Intervention: Pulse palpation (touch)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combined cold pressor/pulse palpation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cold pressor test (stressor)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 60
Study: 2234818

Group type: EXPERIMENTAL
Intervention: Panretinal photocoagulation (PRP) in group A
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Panretinal photocoagulation (PRP) in group B
Number of subjects: 53

Group type: COMPARATOR
Intervention: Comparison between group B and A after PRP
Number of subjects: 53

Group type: COMPARATOR
Intervention: Regression of neovascularization and visual acuity
Number of subjects: 53
Study: 358845

Group type: EXPERIMENTAL
Intervention: Dextro-amphetamine
Number of subjects: 13
Study: 31625020

Group type: EXPERIMENTAL
Intervention: High expression of CD3, CD4, CD8, and CD45RO at the invasive margin (IM)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: High expression of CD4 and FOXP3 at the tumor center (TC)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Combined marker of CD3, CD8, CD45RO, and FOXP3
Number of subjects: 88
Study: 31302291

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 27256706

Group type: EXPERIMENTAL
Intervention: High dose hUCB-MSCs (5.0 × 10^7)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Low dose hUCB-MSCs (2.5 × 10^7)
Number of subjects: 34
Study: 26357928

Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: CPAP(Flex)
Number of subjects: 400
Study: 23179858

Group type: EXPERIMENTAL
Intervention: Glibenclamide (Gb) 3.5 mg, intravenously or orally
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Metabolite M1 3.5 mg, intravenously
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Metabolite M2 3.5 mg, intravenously
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 21654053

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/d for six months
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (lower doses of statins)
Number of subjects: 100
Study: 19505424

Group type: EXPERIMENTAL
Intervention: L-ornithine L-aspartate (LOLA) infusion (30 g daily for 3 days)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 201
Study: 16861744

Group type: EXPERIMENTAL
Intervention: Vaginoscopic hysteroscopy (Group A)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Traditional hysteroscopy (Group B)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Phase I of the procedure (Group A)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Phase I of the procedure (Group B)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Duration of hysteroscopy
Number of subjects: 300
Study: 15531007

Group type: EXPERIMENTAL
Intervention: Duloxetine 40 mg/d
Number of subjects: 1139

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg/d
Number of subjects: 1139

Group type: EXPERIMENTAL
Intervention: Duloxetine 80 mg/d
Number of subjects: 1139

Group type: EXPERIMENTAL
Intervention: Duloxetine 120 mg/d
Number of subjects: 1139

Group type: COMPARATOR
Intervention: Paroxetine 20 mg/d
Number of subjects: 1139

Group type: COMPARATOR
Intervention: Fluoxetine 20 mg/d
Number of subjects: 1139

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1139

Group type: EXPERIMENTAL
Intervention: Duloxetine (any dose)
Number of subjects: 1139
Study: 11531952

Group type: EXPERIMENTAL
Intervention: HAART + IL-2
Number of subjects: 0

Group type: COMPARATOR
Intervention: HAART alone
Number of subjects: 0
Study: 9184112

Group type: EXPERIMENTAL
Intervention: 1‐(quinoxalin‐6 ylcarbonyl)piperidine (CX516)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8486876

Group type: EXPERIMENTAL
Intervention: 500 ml 20% Lipofundin MCT/LCT (1/1) per day
Number of subjects: 20

Group type: COMPARATOR
Intervention: 500 ml 20% Lipofundin S (LCT) infused over 8 h each evening
Number of subjects: 20
Study: 3497041

Group type: EXPERIMENTAL
Intervention: Troleandomycin 2 g/day p.o. for 7 days
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 30074935

Group type: EXPERIMENTAL
Intervention: Intravenous ferric carboxymaltose
Number of subjects: 100

Group type: COMPARATOR
Intervention: Oral ferrous sulfate
Number of subjects: 100
Study: 26952706

Group type: EXPERIMENTAL
Intervention: Both-bone intramedullary nailing
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Intramedullary nailing of ulna and plate fixation of radius
Number of subjects: 87

Group type: COMPARATOR
Intervention: Both-bone plate fixation
Number of subjects: 87
Study: 24531024

Group type: EXPERIMENTAL
Intervention: Superior LPI
Number of subjects: 208

Group type: COMPARATOR
Intervention: Temporal LPI
Number of subjects: 208
Study: 22108528

Group type: EXPERIMENTAL
Intervention: 10-week in-season resistance training program (EG)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 25
Study: 19884374

Group type: EXPERIMENTAL
Intervention: Nemonoxacin (TG-873870) 75 to 1,000 mg once daily for 10 days
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Nemonoxacin (TG-873870) 500 mg cohort
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Nemonoxacin (TG-873870)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 18195171

Group type: EXPERIMENTAL
Intervention: Egg consumption of 1 per day
Number of subjects: 21275

Group type: EXPERIMENTAL
Intervention: Egg consumption of >= 2 per day
Number of subjects: 21275

Group type: COMPARATOR
Intervention: Egg consumption of < 1 per week
Number of subjects: 21275

Group type: COMPARATOR
Intervention: Egg consumption of up to 6 times per week
Number of subjects: 21275

Group type: EXPERIMENTAL
Intervention: Egg consumption of >= 7 per week
Number of subjects: 21275

Group type: EXPERIMENTAL
Intervention: HF without antecedent myocardial infarction
Number of subjects: 21275
Study: 16870075

Group type: EXPERIMENTAL
Intervention: P‐ERMS (KADIAN) once‐daily (QD) dosing
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: CRO (OxyContin) twice‐daily (BID) dosing
Number of subjects: 112
Study: 12965981

Group type: EXPERIMENTAL
Intervention: 3.95%‐tetrahydrocannabinol marijuana cigarette
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: 2.5‐mg dronabinol (delta‐9‐tetrahydrocannabinol) capsule
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo capsule
Number of subjects: 67
Study: 11789210

Group type: EXPERIMENTAL
Intervention: Shenmai injection (SM) with oxygen inhalation and anti-infection agents (SM 40 ml + 10% glucose 100 ml)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Aminophylline (AP) with 10% glucose (AP 0.25 g plus 10% glucose 100 ml)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Both groups (SM and AP)
Number of subjects: 64